Sign in

CIK 0001714899

  • Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
463872213
Phone
+1 650-866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Open-market sale Director sold 30,000 shares at $70.05 ($2,101,590)
  2. 4 Open-market sale Director sold 10,000 shares at $60.03 ($600,310)
  3. 4 Open-market sale Director sold 10,000 shares at $50.18 ($501,830)
  4. 4 Open-market sale Chief Medical Officer sold 52,906 shares at an average $40.74 ($2,155,603)
  5. 3 Insider Initial Statement of Ownership
  6. 4 Open-market sale Chief Medical Officer sold 3,689 shares at $31.00 ($114,359)
  7. 4 Shares withheld for taxes Chief Medical Officer gave up 1,954 shares (to pay taxes)
  8. 4 Shares withheld for taxes COO and Secretary gave up 1,954 shares (to pay taxes)
  9. 4 Shares withheld for taxes CFO and Treasurer gave up 1,954 shares (to pay taxes)
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Open-market sale 10% owner sold 1,443,247 shares at $31.65 ($45,678,768)
  15. 4 Open-market sale 10% owner sold 250,000 shares at an average $23.97 ($5,993,052)
  16. 4 Open-market sale 10% owner sold 255,000 shares at an average $24.72 ($6,304,373)
  17. 4 Gift President and CEO gave 40,000 shares (gift)
  18. 4 Open-market sale Director sold 400,000 shares at $26.10 ($10,440,000)
  19. 4 Open-market sale 10% owner sold 1,922,855 shares at $25.75 ($49,513,516)
  20. 4 Derivatives Options or other derivatives

Page 15 of 22 · 436 filings